Ban katantaSwati Tole, Senior Group Medical Director, Genentech, a member of the Roche Group, explains the challenges around treating ulcerative colitis and Crohn’s disease and how Roche’s vision for personalised healthcare in IBD could contribute to better outcomes for patients.
Imagine trying to complete a jigsaw puzzle but only having half the pieces. You manage to piece together one or two sections, but many others remain a mystery, and you are never able to see the complete picture. In some ways, this is what it has been like for doctors treating inflammatory bowel diseases (IBD).
IBD (see here for what is IBD) is a highly complex disease and – just like that jigsaw puzzle – we do not have all the pieces at our disposal to see the full picture. IBD is actually not one single disease but rather a group of long-term disorders, including ulcerative colitis (UC) and Crohn’s disease (CD). And each disease under the umbrella of IBD can vary hugely from person to person.
Different patients can experience different symptoms, and these can also differ from day to day. For some patients, pain is the most important problem, for others it might be fatigue. Furthermore, there are differences in terms of what symptoms mean to people. A mother with two children has different needs than a student. In order to find the right treatment for the right patient, patients need to be involved in the discussion and we need to move towards genuine shared decision making.” – Luisa Avedano, CEO, European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA)
Ban katantaThe variation is because IBD’s causes and drivers are so complex. There are some genetic elements at play, but these are not enough to explain the majority of IBD cases.
So, what’s the secret to seeing the full picture of IBD? It may come down to collecting more puzzle pieces: researchers believe that there is a range of factors that are important for disease development, including environmental, genetic and immune factors, so it is important to look at them all together.
One recent exciting line of research has focused on the role of the gut microbiome Ban katanta– that is, the vast ecosystem of over 100 trillion microorganisms that live inside our guts – and its influence on human metabolism, immune responses and the nervous system. These microorganisms could hold important clues to the development and potential treatment of inflammatory bowel diseases.
Moving away from trial and error
The complexity of the condition makes IBD management very difficult. It is estimated that about 80% of people with IBD do not experience long-term remission.1
Ban katantaDoctors do have some treatments at their disposal, but have no way of knowing in advance how well they will work in each patient.
Ban katantaIf we could predict the potential course and severity of disease, then it would alter the way we treat patients: we could do so in a personalised manner, rather than over or undertreating them through a ‘trial and error’ approach.
Many patients are either delayed from going onto the best treatment for them, or are put on treatments that provide little or no benefit to them. This is not the doctors’ fault – there just simply has been no way for doctors to know which treatment will work for the right patient at the right time, so it’s currently trial-and-error.” - Amanda R. Tatro, Group Global Scientific Director at Roche
Making it personal
This is where personalised healthcare (PHC) and precision medicine come in. Personalised healthcare is about moving away from a ‘one size fits all’ approach, towards a situation where treatment and care decisions can be taken based on an individual’s predicted response or risk of disease or personal preferences. This is not a new concept – it has been an area of research for Roche in cancer and other diseases for many years – but it is only recently that it has become a possibility in the management of ulcerative colitis and Crohn’s disease.
“Our goal is to help people to be on the right therapy at the right time,” says Amanda. “The ideal situation is knowing when the right moment is to intervene and the right treatment that each person will respond to. PHC is about having a personalised care plan and using the tools we have in the most appropriate way for each patient.”
Finding patterns of disease
Ban katantaSo, how far along are we in achieving that goal? While personalised healthcare has mostly been focused on finding predictive biomarkers for specific therapies – that is, specific molecules or genes that signpost an increased or decreased chance of treatment success in those who have them – the potential for personalised healthcare in IBD goes much further than this. By collecting all the various pieces of the puzzle from a variety of sources, we can piece them together and see the bigger picture.
Ban katantaAcross clinical trials, we collect huge amounts of information – genetic information, tissue and stool samples, colonoscopy images, as well as clinical data – to assess how the disease behaves before and during therapy. We collect this information from people with IBD across all ages, genders and ethnicities. We also collect patient-reported outcomes and other sources of real-world data to truly understand how the disease is behaving in different people, and we look at promising research such as the microbiome.
All of this information is examined using advanced analytics – machine learning and artificial intelligence – to help us identify patterns and better understand what is driving the disease in specific ‘clusters’ of patients with IBD. From this we can come up with ways to deliver better care for them.
Ban katanta“We are looking at finding patterns in disease to help us identify who would benefit from accelerated therapy or more aggressive therapy from the start,” explains Swati Tole, Senior Group Medical Director at Genentech. “We are also looking at indicators to predict key symptoms such as flares in patients, which would help doctors to escalate therapy before events worsen. It’s about applying the patterns we find to each patient to ensure we are treating them as optimally as possible throughout the entire journey of their disease.”
IBD is an area of real unmet need where there is the potential to make a significant difference to patients’ lives.
“Every week in my day-to-day life I hear about someone else who is diagnosed or whose children have been diagnosed with IBD,” says Swati. “I believe that we can make a real difference to these patients. We are really excited and inspired about what we can achieve and we are fully committed to doing so.”
1) Sandborn W. The Present and Future of Inflammatory Bowel Disease Treatment. Gastroenterol Hepatol (N Y). 2016 Jul; 12(7): 438–441.